Mark Huber, MD
Hematology & Oncology · Sioux Falls, SDNPI 1750357299
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,000 of the $1,182 with a category attached, or 84.6%. Sirtex Medical Inc accounts for 84.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $1,000 and has fallen 93.3% since, to $67 in 2025.
Across 12 payments — averaging $98.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sirtex Medical Inc$1K
- Pfizer$67
- Merck$41
- Acrotech Biopharma Inc.$26
- E.r. Squibb & Sons, L.L.C.$13
- Gilead$12
- plus $23 from 2 others
Across 1 payment — averaging $4059.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4K
What the payments were for
- Speaking & faculty fees$1,00085%
- Food & beverage$383%
- Education$14412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sirtex Medical Inc | 1 | $1,000 |
| Pfizer | 3 | $67 |
| Merck | 2 | $41 |
| Acrotech Biopharma Inc. | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Gilead | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
| Deciphera Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIR-Spheres Microspheres$1,000
How this compares
$1,182 in reported general payments places this provider in the 65th percentile of 28 hematology & oncology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 120 | $1,630,911 |
| CabometyxCabozantinib S-Malate | 41 | $1,134,576 |
| XtandiEnzalutamide | 81 | $1,004,746 |
| JakafiRuxolitinib Phosphate | 46 | $663,192 |
| CalquenceAcalabrutinib Maleate | 42 | $616,551 |
| NubeqaDarolutamide | 50 | $616,427 |
| ImbruvicaIbrutinib | 34 | $503,440 |
| TagrissoOsimertinib Mesylate | 29 | $495,708 |
| RevlimidLenalidomide | 30 | $491,120 |
| LynparzaOlaparib | 23 | $313,588 |
| LonsurfTrifluridine/Tipiracil Hcl | 21 | $298,739 |
| XalkoriCrizotinib | 12 | $274,508 |
| SprycelDasatinib | 14 | $268,971 |
| MekinistTrametinib Dimethyl Sulfoxide | 17 | $242,188 |
| TafinlarDabrafenib Mesylate | 16 | $209,372 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerXalkori, Eliquis | $67 | $331,72288 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $13 | $268,97114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 28 hematology & oncology providers in South Dakota.
Other hematology & oncology in Sioux Falls
- Kelly McCaulSioux Falls$1.2M
- Roberto Ferro ValdesSioux Falls$142K
- Waqas JehangirSioux Falls$23K
- Steven PowellSioux Falls$13K
- Benjamin SolomonSioux Falls$5K
- Miroslaw MazurczakSioux Falls$2K
- Ryan VacaSioux Falls$1K
- Michael McHaleSioux Falls$811
- Heidi McKeanSioux Falls$552
- Allison WatsonSioux Falls$254
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.